ArticleTherapeutics and clinical risk management2009
Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.
Article in Therapeutics and clinical risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Fluorene derivatives as potent antifungal and antibiofilm agents against fluconazole-resistantBiofilm · 2025Article
- β-Artemether and Lumefantrine Dual Drug Loaded Lipid Nanoparticles: Physicochemical Characterization, Pharmacokinetic Evaluation and Biodistribution Study.Pharmaceutical nanotechnology · 2022Article
- Chemoprophylaxis under sporozoites-lumefantrine (CPS-LMF) immunization induce protective immune responses against3 Biotech · 2021Article
- Effects of lemon decoction on malaria parasite clearance and selected hematological parameters in Plasmodium berghei ANKA infected mice.BMC complementary medicine and therapies · 2020Article
- New insights into the Plasmodium vivax transcriptome using RNA-Seq.Scientific reports · 2016Article
- Primaquine treatment and relapse in Plasmodium vivax malaria.Pathogens and global health · 2016Review
- Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.Antimicrobial agents and chemotherapy · 2014Article
- Synthesis of five- and six-membered cyclic organic peroxides: Key transformations into peroxide ring-retaining products.Beilstein journal of organic chemistry · 2014Review
- Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda.Malaria journal · 2012Article
- Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania.Risk management and healthcare policy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization strongly recommends artemisinin-based combination therapy (ACT) regimens for the treatment of uncomplicated Plasmodium falciparum malaria cases in endemic areas. Among the combinations of compounds that are available at present, excellent results have been obtained for the artemisinin derivative artemether, in a combination galenic preparation with lumefantrine (artemether-lumefantrine, AL). Here, the pharmacological properties and the therapeutic options of both substances are briefly reviewed and a cursory overview is given on recent trials that have compared the therapeutic effects of AL in the standard 6-dose regimen with other antimalarials and combinations. In order to ensure the most achievable and reliable adherence and compliance of children in the treatment of malaria, a dispersible formulation of AL is now attainable. Recent reports on the emergence of resistance to ACT regimens in Asia, however, are alarming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.